Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

fast track appraisal

UK POM Digital Estate Benchmark

New benchmark reveals significant digital maturity gap across UK POM companies’ product-information estates

A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development

Genetic Digital

- PMLiVE

NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer

It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year

- PMLiVE

LEO Pharma to acquire Replay gene therapy platform

The acquisition will advance innovation for patients with rare skin diseases

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

Pharma website governance

Why pharma website projects stall long before compliance becomes the problem

Pharma teams often blame compliance when digital projects slow down. In reality, the bigger issue is usually weaker ownership, unclear review models and content structures that were never designed for...

Genetic Digital

- PMLiVE

PharmaQuest returns: EPA perspectives, through a rare disease lens

By Lottie Sequerra and Emily Morton-West

Amiculum

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Havas Life London unveils AI awareness campaign

The campaign highlights the dangers of AI misinformation in rare disease

- PMLiVE

FDA approves first gene therapy for Wiskott-Aldrich syndrome

Symptoms of the rare disease include bleeding, eczema and frequent infections

- PMLiVE

AstraZeneca announces $2bn investment in US manufacturing

The new and expanded facilities will support production of rare disease drug treatments

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links